Companies jointly work on cervical cancer drug
March 08 2005 1:00 AM ET
Minnesota-based 3M and Japanese firm Takeda Pharmaceuticals are jointly developing a drug to treat cervical dysplasia--the precursor to cervical cancer, The Wall Street Journal reports. Cervical dysplasia--abnormal cell growth in the cervix that is considered precancerous--is believed to be linked in almost all cases to certain strains of the human papillomavirus. The experimental drug aims to stimulate the body's immune system to destroy HPV-infected cells in the cervix. The still-unnamed drug is currently in Phase I clinical trials. Phase II tests are expected to begin later this year. Cervical cancer is an AIDS-defining condition in HIV-positive women.
- WATCH: This Indiana Pizzeria Won't Cater Gay Weddings
- Arrow and The Flash Stars: It's Time for a Gay Superhero on TV (Video)
- WATCH: Conan's Hilarious Interview With Indiana's 'Religious Freedom Czar'
- WATCH: Student Defies Russia's Propaganda Ban With Hozier's 'Take Me to Church'
- WATCH: Seth Meyers Takes Down Indiana's New Antigay Legislation
- #TBT: They Died in the Closet